@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_head { this: np:hasAssertion dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_assertion; np:hasProvenance dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_provenance; np:hasPublicationInfo dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_publicationInfo; a np:Nanopublication . dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_assertion a np:Assertion . dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_provenance a np:Provenance . dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_publicationInfo a np:PublicationInfo . } dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_assertion { miriam-gene:3630 a ncit:C16612 . lld:C0011849 a ncit:C7057 . dgn-gda:DGNa5171e2b49d4c15322b78d36ac429fff sio:SIO_000628 miriam-gene:3630, lld:C0011849; a sio:SIO_001121 . } dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_provenance { dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_assertion dcterms:description "[In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:12037147; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP356385.RAvRIoTD6x2O8xOYWWdPpx8Y7skyIwYm-qyz0y0xYCshw130_publicationInfo { this: dcterms:created "2016-05-13T12:44:26+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }